You are here

Otezla

AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis

AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis

Fierce Pharma

Boehringer Ingelheim

Flag link:

Amgen nabs appeals win against Otezla generics, blocking Sandoz and Zydus copycats until 2028

Amgen nabs appeals win against Otezla generics, blocking Sandoz and Zydus copycats until 2028

Fierce Pharma

Flag link:

Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data

Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data

Fierce Biotech

Bristol Myers Squibb

deucravacitinib

clinical trials

Flag link:

Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers

Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers

Fierce Pharma

Bristol Myers Squibb

Flag link:

Amgen builds Otezla’s psoriasis label as rival BMS looms large

Amgen builds Otezla’s psoriasis label as rival BMS looms large

Pharmaforum

Bristol Myers Squibb

deucravacitinib

Flag link:

Amgen's Otezla notches win in genital psoriasis, snagging possible edge against forthcoming BMS rival

Amgen's Otezla notches win in genital psoriasis, snagging possible edge against forthcoming BMS rival

Fierce Pharma

Bristol Myers Squibb

Flag link:

Amgen's Otezla, Repatha and biosimilars put on notice, with challenging years ahead

Amgen's Otezla, Repatha and biosimilars put on notice, with challenging years ahead

Fierce Pharma

Flag link:

Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028

Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028

Fierce Pharma

market exclusivity

Flag link:

Otezla maker Amgen challenges patient groups to help fix long-lasting psoriasis treatment gaps

Otezla maker Amgen challenges patient groups to help fix long-lasting psoriasis treatment gaps

Fierce Pharma

Flag link:

Bristol Myers' next-gen immunology med busts Amgen's Otezla in head-to-head study. Is a showdown coming?

Bristol Myers' next-gen immunology med busts Amgen's Otezla in head-to-head study. Is a showdown coming?

Endpoints

Bristol Myers Squibb

deucravacitinib

Flag link:

Amgen Submits Supplemental NDA for Mild-to-Moderate Psoriasis Drug Otezla

Amgen Submits Supplemental NDA for Mild-to-Moderate Psoriasis Drug Otezla

BioSpace

Flag link:

Bristol Myers' psoriasis drug beats Amgen rival in phase 3

Bristol Myers' psoriasis drug beats Amgen rival in phase 3

Fierce Biotech

Bristol-Myers Squibb

deucravacitinib

plaque psoriasis

Flag link:

Thank Otezla for Amgen's Q3 Revenue and Earnings Beats

Thank Otezla for Amgen's Q3 Revenue and Earnings Beats

Motley Fool

Flag link:

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

Pharmaforum

clinical trials

Flag link:

AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included

AbbVie's Skyrizi stands to gain as docs move away from older psoriasis meds—Amgen's Otezla included

Fierce Pharma

Flag link:

Amgen ramps up Otezla expansion effort with positive data in mild psoriasis

Amgen ramps up Otezla expansion effort with positive data in mild psoriasis

Fierce Pharma

Flag link:

Amgen to test psoriasis pill Otezla in COVID-19

Amgen to test psoriasis pill Otezla in COVID-19

Pharmaforum

clinical trials

Flag link:

Amgen's anti-inflammatory Otezla makes its foray into COVID-19

Amgen's anti-inflammatory Otezla makes its foray into COVID-19

Fierce Pharma

Flag link:

Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

Fierce Pharma

Flag link:

[podcast+transcript]Why Amgen's Spending Billions to Buy This 1 Drug

[podcast+transcript]Why Amgen's Spending Billions to Buy This 1 Drug

Motley Fool

Bristol-Myers Squibb

Flag link:

Pages